Efficacy and safety of doxycycline in pelvic inflammatory disease: a systematic review and meta-analysis

DOI

https://dx.doi.org/10.18565/aig.2025.176

Mezhevitinova E.A., Kepsha M.A., Ilyasova N.A., Zatevalov A.M.
1) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia

Objective: To evaluate the clinical and microbiological efficacy, as well as the safety of doxycycline as part of combination therapy in women with pelvic inflammatory disease (PID).
Materials and methods: The systematic review and meta-analysis were conducted in accordance with the PRISMA checklist. The analysis included randomized controlled trials published from 1967 to June 2025 that assessed the efficacy and safety of doxycycline in various treatment regimens for PID in women aged over 18 years. An electronic search was conducted in PubMed, Cochrane Library, Google Scholar, and ClinicalTrials.gov. The risk of bias was assessed using the RoB-2 tool.
Results: The qualitative and quantitative analysis included eight randomized clinical trials with a total of 1,881 patients. The meta-analysis revealed that clinical efficacy of doxycycline was comparable to that of alternative treatment regimens (OR=1.17; 95% CI [0.91; 1.49]; p=0.22). However, microbiological efficacy was significantly higher in the doxycycline group (OR=1.40; 95% CI [1.14; 1.72]; p=0.002). Adverse events, mainly related to the gastrointestinal tract, were more frequently observed in regimens including doxycycline, presumably due to the use of its hydrochloride form.
Conclusion: Doxycycline, especially in the form of monohydrate, is an effective and rational component of combination therapy for women with PID, as it provides high microbiological eradication rates with acceptable tolerability. Further research with standardized outcome criteria and extended follow-up is required to clarify its role in therapeutic algorithms.

Authors’ contributions: Kepsha M.A., Ilyasova N.A. – developing the concept and design of the study, literature search and analysis, manuscript writing, approval of the final version of the article; Zatevalov A.M. – statistical data processing; Mezhevitinova E.A. – editing the text, approval of the final version of the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Mezhevitinova E.A., Kepsha M.A., Ilyasova N.A., Zatevalov A.M. Efficacy and safety of
doxycycline in pelvic inflammatory disease: a systematic review and meta-analysis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (7): 27-38 (in Russian)
https://dx.doi.org/10.18565/aig.2025.176

doxycycline

pelvic inflammatory disease

PID

antibacterial therapy

doxycycline monohydrate

dispersible tablets

Full text (in Russian)

De Francesco M.A., Stefanelli P., Carannante A., Corbellini S., Giagulli C., Lorenzin G. et al. Management of a case of peritonitis due to Neisseria gonorrhoeae infection following pelvic inflammatory disease (PID). Antibiot. (Basel). 2020; 9(4): 193. https://dx.doi.org/10.3390/antibiotics9040193
Oroz C., Bailey H., Hollows K., Lee J., Mullan H., Theobald N. A national audit on the management of pelvic inflammatory disease in UK genitourinary medicine clinics. Int. J. STD AIDS. 2012; 23(1): 53-4. https://dx.doi.org/10.1258/ijsa.2011.011183
Jenkins S.M., Vadakekut E.S. Pelvic inflammatory disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025.
He D., Wang T., Ren W. Global burden of pelvic inflammatory disease and ectopic pregnancy from 1990 to 2019. BMC Public Health. 2023; 23(1): 1894. https://dx.doi.org/10.1186/s12889-023-16663-y
Greydanus D.E., Bacopoulou F. Acute pelvic inflammatory disease: a narrative review. Pediatr. Med. 2019; 2: 36. https://dx.doi.org/10.21037/pm.2019.07.05
Centers for Disease Control and Prevention (CDC). Pelvic inflammatory disease (PID) – STI treatment guidelines, 2021 [Internet]. Atlanta: U.S. Department of Health and Human Services, 2021. Available at: https://www.cdc.gov/std/treatment-guidelines/pid
Sharma H., Tal R., Clark N.A., Segars J.H. Microbiota and pelvic inflammatory disease. Semin. Reprod. Med. 2014; 32(1): 43-9. https://dx.doi.org/10.1055/s-0033-1361822
Abdel-Aleem H., D’Arcangues C., Vogelsong K., Gülmezoglu A.M. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst. Rev. 2007; (2): CD003449. https://dx.doi.org/10.1002/14651858.CD003449.pub2
World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva: WHO, 2021. 148 p. Available at: https://www.who.int/publications/i/item/9789240024168
Министерство здравоохранения Российской Федерации. Воспалительные болезни женских тазовых органов. Клинические рекомендации. М.; 2024. 49 с. [Ministry of Health of the Russian Federation. Inflammatory diseases of female pelvic organs. Clinical guidelines. Moscow; 2024. 49 p. (in Russian)].
British Association for Sexual Health and HIV. BASHH guidelines [Internet]. Available at: https://www.bashh.org/resources/guidelines/ Accessed 2025, Jun 29.
Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. https://dx.doi.org/10.1136/bmj.n71
Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A., eds. Cochrane handbook for systematic reviews of interventions (version 6.1., 2020). Available at: www.training.cochrane.org/handbook
National Heart, Lung and Blood Institute. Study quality assessment tools. 2021. Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Martens M.G., Gordon S., Yarborough D.R., Faro S., Binder D., Berkeley A. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. South. Med. J. 1993; 86(6): 604-10. https://dx.doi.org/10.1097/00007611-199306000-00002
Heystek M., Ross J.D.C. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int. J. STD AIDS. 2009; 20(10): 690-5. https://dx.doi.org/10.1258/ijsa.2008.008495
Savaris R.F., Teixeira L.M., Torres T.G., Edelweiss M.I.A., Moncada J., Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease. Obstet. Gynecol. 2007; 110(1): 53-60. https://dx.doi.org/10.1097/01.AOG.0000268801.90261.27
Bevan C., Ridgway G., Rothermel C. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J. Int. Med. Res. 2003; 31(1): 45-54. https://dx.doi.org/10.1177/147323000303100108
Malhotra M., Sharma J.B., Batra S., Arora R., Sharma S. Ciprofloxacin-tinidazole combination, fluconazole-azithromicin-secnidazole-kit and doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian J. Med. Sci. 2003; 57(12): 549-55.
Arredondo J.L., Diaz V., Gaitan H., Maradiegue E., Oyarzun E., Paz R. et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin. Infect. Dis. 1997; 24(2): 170-8. https://dx.doi.org/10.1093/clinids/24.2.170
Fischbach F., Deckardt R., Graeff H. Ciprofloxacin/Metronidazol vs. Cefoxitin /Doxycyclin: Vergleich zweier therapieschemata zur behandlung der akuten pelvinen Infektion. Geburtshilfe Frauenheilkd. 1994; 54(06): 337-40. https://dx.doi.org/10.1055/s-2007-1022851
Wendel G.D., Cox S.M., Bawdon R.E., Theriot S.K., Heard M.C., Nobles B.J. A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. Am. J. Obstet. Gynecol. 1991; 164(5): 1390-6. https://dx.doi.org/10.1016/0002-9378(91)91479-G
Kadayifci A., Gulsen M.T., Koruk M., Savas M.C. Doxycycline-induced pill esophagitis. Dis. Esophagus. 2004; 17(2): 168-71. https://dx.doi.org/10.1111/j.1442-2050.2004.00384.x
Cagin Y.F., Atayan Y., Erdogan M.A., Cetin C., Ak G., Dagtekin F. et al. Doxycycline induced esophageal ulcer: two cases report. Medicine Science. 2015; 4(1): 1966-71. https://dx.doi.org/10.5455/medscience.2014.03.8192
Graber E.M. Treating acne with the tetracycline class of antibiotics: a review. Dermatol. Rev. 2021; 2(6): 321-30. https://dx.doi.org/10.1002/der2.49
Яковлев С.В., Сидоренко С.В.. Рафальский В.В., Спичак Т.В., ред. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации. М.: Пре100 Принт; 2016. 144 с. [Yakovlev S.V., Sidorenko S.V., Rafalsky V.V., Spichak T.V., eds. Strategy and tactics of rational use of antimicrobial agents in outpatient practice. Eurasian clinical guidelines. Moscow: Pre100 Print; 2016. 144 p. (in Russian)].
Государственный реестр лекарственных средств. Перечень взаимозаменяемых лекарственных препаратов. [State Register of Medicines. List of interchangeable medicinal products. (in Russian)]. https://grls.rosminzdrav.ru/Default.aspx
Инструкция по применению препарата «Доксициклин ЭКСПРЕСС». [Instructions for use of the drug "Doxycycline EXPRESS". (in Russian)]. https://doksiciklin.ru/express/?ysclid=mcx8qmlplo931960358

Received 30.06.2025

Accepted 11.07.2025

Elena A. Mezhevitinova, Dr. Med. Sci., Leading Researcher at the Scientific and Outpatient Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 4 Ac. Oparin str., Moscow, 117997, Russia, mejevitinova@mail.ru,
https://orcid.org/0000-0003-2977-9065
Maria A. Kepsha, Junior Researcher, Physician at the Scientific and Outpatient Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 4 Ac. Oparin str., Moscow, 117997, Russia, m_kepsha@oparina4.ru, https://orcid.org/0000-0002-4201-1360
Natalya A. Ilyasova, Researcher at the Department of International Cooperation, Obstetrician-Gynecologist at the Scientific and Outpatient Department, V.I. Kulakov
National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 4 Ac. Oparin str., Moscow, 117997, Russia,
natalia_ilyasova@mail.ru, https://orcid.org/0000-0003-0665-3515
Alexander M. Zatevalov, PhD, Senior Researcher at the Laboratory of Systems Biology of Aging and Geroprotective Technologies, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 4 Ac. Oparin str., Moscow, 117997, Russia; Deputy Director for Innovation Development and Technology, G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 10 Admiral Makarov str., Moscow, 125212, Russia, a_zatevalov@oparina4.ru, https://orcid.org/0000-0002-1460-4362

Efficacy and safety of doxycycline in pelvic inflammatory disease: a systematic review and meta-analysis

Mezhevitinova E.A., Kepsha M.A., Ilyasova N.A., Zatevalov A.M.

Keywords

References

About the Authors

Similar Articles